Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Markets saw a volatile session with Nifty trading below the 23,800-24,000 resistance zone, though select heavyweight buying limited downsid...

Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...

Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the J...

Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business press...

Biocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...

Wockhardt shares saw a significant jump on Tuesday. The pharmaceutical company reported a strong turnaround in its March quarter performanc...

Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...

Sun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...

Sun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Biocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...

Joining Indian pharma majors who are targeting the $65-billion global biotech drug market.